Universities should not have to bow to research institutes, writes Debashis Gangopadhyay. Basic Sciences versus Applied Sciences Undermining humanities studies in schools will lead to a large number of science graduates in the market. This is a boon for multinational companies as profits will escalate — the cost of labour being lower. However, the danger to profits persist from another aspect. Students who study science out of their love for a subject are...

-The Economic Times A growing number of countries are adopting India's intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health. Although multinational companies have criticised India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina and the Philippines are adopting similar provisions. Last month, China amended its IP laws, allowing local companies to produce low-cost versions...

-The Hindu The World Health Organisation (WHO) has put in place a mechanism to define counterfeit medical products. The set of definitions of sub-standard, spurious, falsely labelled, falsified and counterfeit products will be globally accepted and help to bring about uniformity in identifying such drugs, without interrupting worldwide supplies. The decision to establish a member state mechanism was taken at the World Health Assembly, the WHO's policymaking body, at a meeting held recently. The...

-India Today A top agricultural research official's idea that India's age-old plant genetic resources can be made available to MNCs in return for better technology for farmers has invited criticism from non-governmental groups as well as individuals. Dr S. K. Datta, Indian Council of Agricultural Research (ICAR) deputy director-general for crop science, claimed that many of India's plant germplasm or species were in the public domain and already being used by MNCs...

Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs' claims of cheap access and affordability for patented drugs. Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments...